Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Matthias Boentert. (2019) Sleep disturbances in patients with amyotrophic lateral sclerosis: current perspectives. Nature and Science of Sleep 11, pages 97-111.
Read now
Read now
. (2019) Theme 9 Clinical trials and trial design. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 20:sup1, pages 262-288.
Read now
Read now
Joseph M. Palumbo, Jean Hubble, Stephen Apple, Koji Takei, Kikumi Tsuda, Shawn Liu, Jeffrey Zhang & Wendy Agnese. (2019) Post-hoc analyses of the edaravone clinical trials Study 16 and Study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 20:5-6, pages 421-431.
Read now
Read now
Richard Bedlack. (2019) ALSUntangled No. 47: RT001. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 20:3-4, pages 294-297.
Read now
Read now
Hiide Yoshino. (2019) Edaravone for the treatment of amyotrophic lateral sclerosis. Expert Review of Neurotherapeutics 19:3, pages 185-193.
Read now
Read now
. (2017) Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:sup1, pages 55-63.
Read now
Read now
Alexander Kalin, Elvia Medina-Paraiso, Kaoru Ishizaki, Alex Kim, Yannong Zhang, Takanori Saita & Masahiko Wasaki. (2017) A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:sup1, pages 71-79.
Read now
Read now
Nicholas J. Maragakis. (2017) What can we learn from the edaravone development program for ALS?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:sup1, pages 98-103.
Read now
Read now
Koji Takei, Kikumi Tsuda, Fumihiro Takahashi, Manabu Hirai & Joseph Palumbo. (2017) An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:sup1, pages 88-97.
Read now
Read now
Koji Takei, Kazutoshi Watanabe, Satoshi Yuki, Makoto Akimoto, Takeshi Sakata & Joseph Palumbo. (2017) Edaravone and its clinical development for amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:sup1, pages 5-10.
Read now
Read now
Yoshinobu Nakamaru, Shuji Kinoshita, Atsuhiro Kawaguchi, Koji Takei, Joseph Palumbo & Masayuki Suzuki. (2017) Pharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populations. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:sup1, pages 80-87.
Read now
Read now
Muzammil Arif Din Abdul Jabbar, Ling Guo, Sonakshi Nag, Yang Guo, Zachary Simmons, Erik P. Pioro, Savitha Ramasamy & Crystal Jing Jing Yeo. Predicting amyotrophic lateral sclerosis (ALS) progression with machine learning. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 0:0, pages 1-14.
Read now
Read now
Articles from other publishers (24)
Hidetoshi Shimizu, Yukiko Nishimura, Youichi Shiide, Makoto Akimoto, Makiko Yashiro, Masaki Ueda, Manabu Hirai, Hiide Yoshino, Tomohiko Mizutani, Kazuaki Kanai, Osamu Kano, Hideki Kimura, Hisakuni Sekino & Kimiko Ito. (2023) Pharmacokinetics of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis. Clinical Therapeutics.
Crossref
Crossref
Elena Grossini, Fabiola De Marchi, Sakthipriyan Venkatesan, Angelica Mele, Daniela Ferrante & Letizia Mazzini. (2023) Effects of Acetyl-L-Carnitine on Oxidative Stress in Amyotrophic Lateral Sclerosis Patients: Evaluation on Plasma Markers and Members of the Neurovascular Unit. Antioxidants 12:10, pages 1887.
Crossref
Crossref
Shubadra Priyadarshini & Senda Ajroud-Driss. (2023) Update on ALS Treatment. Current Treatment Options in Neurology 25:7, pages 199-212.
Crossref
Crossref
Katarzyna Ciećwierska, Dorothée Lulé, Maksymilian Bielecki, Olga Helczyk, Anna Maksymowicz-Śliwińska, Julia Finsel, Krzysztof Nieporęcki, Peter M. Andersen, Albert C. Ludolph & Magdalena Kuźma-Kozakiewicz. (2023) Quality of life and depression in patients with amyotrophic lateral sclerosis – does the country of origin matter?. BMC Palliative Care 22:1.
Crossref
Crossref
Anas Zakarya Nourelden, Ibrahim Kamal, Abdulrahman Ibrahim Hagrass, Abdelrahman G. Tawfik, Mahmoud M. Elhady, Ahmed Hashem Fathallah, Mona Muhe Eldeen Eshag & Mohamed Sayed Zaazouee. (2023) Safety and efficacy of edaravone in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis. Neurological Sciences.
Crossref
Crossref
Angela Genge, Gary L. Pattee, Gen Sobue, Masashi Aoki, Hiide Yoshino, Philippe Couratier, Christian Lunetta, Susanne Petri, Daniel Selness, Sachin Bidani, Manabu Hirai, Takeshi Sakata, Alejandro Salah, Stephen Apple, Art Wamil, Alexander Kalin & Carlayne E. Jackson. (2022) Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment. Muscle & Nerve 67:2, pages 124-129.
Crossref
Crossref
Toru Yamashita, Yumiko Nakano, Ryo Sasaki, Koh Tadokoro, Yoshio Omote, Taijun Yunoki, Yuko Kawahara, Namiko Matsumoto, Yuki Taira, Chika Matsuoka, Ryuta Morihara & Koji Abe. (2023) Safety and Clinical Effects of a Muse Cell-Based Product in Patients With Amyotrophic Lateral Sclerosis: Results of a Phase 2 Clinical Trial. Cell Transplantation 32.
Crossref
Crossref
Mengxia Gao, Lingqun Zhu, Jingling Chang, Tianyu Cao, Lianying Song, Chunli Wen, Yi Chen, Yudi Zhuo & Fei Chen. (2022) Safety and Efficacy of Edaravone in Patients with Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-analysis. Clinical Drug Investigation 43:1, pages 1-11.
Crossref
Crossref
Fumihiro Takahashi, Osamu Kano, Yoshito Nagano, Takatomo Yoneoka, Sally Nelson & Yoshiteru Ushirogawa. (2022)
Associations between urate levels and amyotrophic lateral sclerosis functional score with edaravone treatment: Post hoc analysis of studies
MCI186
‐16,
MCI186
‐17, and
MCI186
‐19
. Muscle & Nerve 66:5, pages 583-592.
Crossref
Crossref
Paolo Tornese, Stefania Lalli, Antoniangela Cocco & Alberto Albanese. (2022) Review of disease-modifying drug trials in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery & Psychiatry 93:5, pages 521-529.
Crossref
Crossref
Hidetoshi Shimizu, Yukiko Nishimura, Youichi Shiide, Kaori Yoshida, Manabu Hirai, Munetomo Matsuda, Yoshinobu Nakamaru, Yuichiro Kato & Kazuoki Kondo. (2021) Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects. Clinical Pharmacology in Drug Development 10:10, pages 1188-1197.
Crossref
Crossref
Hidetoshi Shimizu, Yukiko Nishimura, Yoichi Shiide, Hideaki Matsuda, Makoto Akimoto, Munetomo Matsuda, Yoshinobu Nakamaru, Yuichiro Kato & Kazuoki Kondo. (2021) Evaluation of Pharmacokinetics, Safety, and Drug‐Drug Interactions of an Oral Suspension of Edaravone in Healthy Adults. Clinical Pharmacology in Drug Development 10:10, pages 1174-1187.
Crossref
Crossref
Rakesh Sahu, Shubham Upadhayay & Sidharth Mehan. (2021) Inhibition of extracellular regulated kinase (ERK)-1/2 signaling pathway in the prevention of ALS: Target inhibitors and influences on neurological dysfunctions. European Journal of Cell Biology 100:7-8, pages 151179.
Crossref
Crossref
Kaoru Ishizaki, Kenta Yoshimura, Kengo Yoshida, Masao Matsuda, Yutaka Kawaguchi, Satoshi Yuki & Gen Sobue. (2021) Real‐world safety of the novel, free radical scavenger edaravone for amyotrophic lateral sclerosis patients: Data from the post‐marketing surveillance SUNRISE Japan. Neurology and Clinical Neuroscience 9:3, pages 223-229.
Crossref
Crossref
Jessica R. Morrice, Michael Kuo & Christopher A. Shaw. 2021. Spectrums of Amyotrophic Lateral Sclerosis. Spectrums of Amyotrophic Lateral Sclerosis
181
199
.
Bhaskar Roy & Robert Griggs. (2021) Advances in Treatments in Muscular Dystrophies and Motor Neuron Disorders. Neurologic Clinics 39:1, pages 87-112.
Crossref
Crossref
Toru Yamashita, Yoshihiro Kushida, Shohei Wakao, Koh Tadokoro, Emi Nomura, Yoshio Omote, Mami Takemoto, Nozomi Hishikawa, Yasuyuki Ohta, Mari Dezawa & Koji Abe. (2020) Therapeutic benefit of Muse cells in a mouse model of amyotrophic lateral sclerosis. Scientific Reports 10:1.
Crossref
Crossref
Juan Fernando Ortiz, Sawleha Arshi Khan, Amr Salem, Zayar Lin, Zafar Iqbal & Nusrat Jahan. (2020) Post-Marketing Experience of Edaravone in Amyotrophic Lateral Sclerosis: A Clinical Perspective and Comparison With the Clinical Trials of the Drug. Cureus.
Crossref
Crossref
Chihiro Kawano, Yurika Isozaki, Ayumi Nakagawa, Takeshi Hirayama, Kazutoshi Nishiyama & Masakazu Kuroyama. (2020) Liver Injury Risk Factors in Amyotrophic Lateral Sclerosis Patients Treated with RiluzoleLiver Injury Risk Factors in Amyotrophic Lateral Sclerosis Patients Treated with Riluzole. YAKUGAKU ZASSHI 140:7, pages 923-928.
Crossref
Crossref
Matthias Boentert. (2020) Sleep and Sleep Disruption in Amyotrophic Lateral Sclerosis. Current Neurology and Neuroscience Reports 20:7.
Crossref
Crossref
Tereza Filipi, Zuzana Hermanova, Jana Tureckova, Ondrej Vanatko & Miroslava Anderova. (2020) Glial Cells—The Strategic Targets in Amyotrophic Lateral Sclerosis Treatment. Journal of Clinical Medicine 9:1, pages 261.
Crossref
Crossref
Jin-Mo Park, Sun-Young Kim, Donghwi Park & Jin-Sung Park. (2019) Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients. Neurological Sciences 41:1, pages 119-123.
Crossref
Crossref
Alex G. Karanevich, Luke J. Weisbrod, Omar Jawdat, Richard J. Barohn, Byron J. Gajewski, Jianghua He & Jeffrey M. Statland. (2018) Using automated electronic medical record data extraction to model ALS survival and progression. BMC Neurology 18:1.
Crossref
Crossref
Said R Beydoun & Jeffrey Rosenfeld. (2018) Edaravone in Amyotrophic Lateral Sclerosis’Lessons from the Clinical Development Program and the Importance of a Strategic Clinical Trial Design. US Neurology 14:1, pages 47.
Crossref
Crossref